Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Jun Masuda(The Cancer Institute Hospital), Toshimi Takano(The Cancer Institute Hospital)

Journal for ImmunoTherapy of Cancer

September 1, 2023

10.1136/jitc-2023-007126

Cited by 65

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

|Journal of Clinical Oncology|2020|222

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

|European Journal of Cancer|2015|150

P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study.

|Cancer Research|2011|15

Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

|Circulation Journal|2025|1